Just weeks ahead of the planned resubmission of the FDA new drug application for a pain pill tailored to reduce opioid-induced nausea and vomiting (OINV), one-time backer Daiichi Sankyo Co. Ltd. handed rights to the drug back to Charleston Laboratories Inc. and booked a ¥27.8 billion (US$252.7 million) loss on the project as it reevaluates its U.S. pain drug strategy. An NDA submitted for the candidate, CL-108, drew a complete response letter (CRL) in February, though neither company revealed why.